Atara Biotherapeutics, Inc. (ATRA)
9.48
+1.02
(+12.06%)
USD |
NASDAQ |
Oct 02, 16:00
9.60
+0.12
(+1.27%)
After-Hours: 20:00
Atara Biotherapeutics Net Income (Quarterly) : -4.834M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.834M |
| March 31, 2026 | -4.145M |
| December 31, 2025 | -3.406M |
| September 30, 2025 | -4.303M |
| June 30, 2025 | 2.387M |
| March 31, 2025 | 38.01M |
| December 31, 2024 | -12.69M |
| September 30, 2024 | -21.91M |
| June 30, 2024 | -19.05M |
| March 31, 2024 | -31.75M |
| December 31, 2023 | -60.45M |
| September 30, 2023 | -69.80M |
| June 30, 2023 | -71.11M |
| March 31, 2023 | -74.77M |
| December 31, 2022 | -74.57M |
| September 30, 2022 | -84.09M |
| June 30, 2022 | 18.47M |
| March 31, 2022 | -88.10M |
| December 31, 2021 | -93.35M |
| September 30, 2021 | -84.66M |
| June 30, 2021 | -83.79M |
| March 31, 2021 | -78.34M |
| December 31, 2020 | -81.31M |
| September 30, 2020 | -74.35M |
| June 30, 2020 | -77.46M |
| Date | Value |
|---|---|
| March 31, 2020 | -73.51M |
| December 31, 2019 | -78.50M |
| September 30, 2019 | -71.90M |
| June 30, 2019 | -74.33M |
| March 31, 2019 | -66.26M |
| December 31, 2018 | -80.01M |
| September 30, 2018 | -58.36M |
| June 30, 2018 | -50.88M |
| March 31, 2018 | -41.44M |
| December 31, 2017 | -35.31M |
| September 30, 2017 | -31.10M |
| June 30, 2017 | -27.43M |
| March 31, 2017 | -25.65M |
| December 31, 2016 | -18.24M |
| September 30, 2016 | -25.37M |
| June 30, 2016 | -18.88M |
| March 31, 2016 | -16.56M |
| December 31, 2015 | -21.25M |
| September 30, 2015 | -11.87M |
| June 30, 2015 | -14.94M |
| March 31, 2015 | -9.16M |
| December 31, 2014 | -10.53M |
| September 30, 2014 | -5.919M |
| June 30, 2014 | -4.511M |
| March 31, 2014 | -7.049M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.63M |
| Total Expenses (Quarterly) | 5.464M |
| EPS Diluted (Quarterly) | -0.3216 |
| Enterprise Value | 131.06M |
| Gross Profit Margin (Quarterly) | 69.68% |
| Profit Margin (Quarterly) | -767.3% |
| Earnings Yield | -14.75% |
| Normalized Earnings Yield | -13.10 |